Researchers at Georgia State University discovered two metabolite-inspired compounds, MLY2 and MLY8, with enhanced anti-inflammatory activity in experimental ulcerative colitis. These compounds showed promise for treating the chronic inflammatory disease, offering an underexplored drug discovery opportunity.
Researchers at KAIST have discovered that VEGF-C brings two VEGFR-3 receptors together, leading to clustering and amplification of lymphangiogenic signaling. This process may provide new strategies for treating related diseases such as lymphedema and cancer metastasis.
New research on Acanthamoeba's mitochondrial metabolism could lead to safer, more effective treatments for eye and brain infections. The study's findings suggest that understanding the amoeba's biochemistry could help develop novel drugs targeting unique proteins involved in building cyst walls.
SLAS Discovery highlights innovative screening platforms and AI-driven analytics for treating oncology, infectious disease, and immunology research. The journal focuses on drug discovery sciences with a strong record of scientific rigor and impact, reporting on research that advances life sciences discovery and technology.
Research in SLAS Technology Vol. 40 explores smartphone glucose sensing and RNA-based therapeutics in Crohn's disease. The publication showcases innovative technologies and scientific advancements in life sciences discovery and development.
New York University researchers have trained an AI model to predict stable tautomers in drug-like molecules, addressing a challenge in molecular design. The model, released as an open-source tool, can analyze large molecular libraries and identify correct tautomer assignments.
A new drug, Kamuvudine K-9, has been shown to preserve nerve fibers and halt neurological damage in a mouse model of multiple sclerosis. The drug, derived from HIV drugs, has been found to be more effective than existing treatments in restoring function and reducing inflammation.
A UCF researcher and her team used AI to screen existing FDA-approved drugs for potential treatments of schwannoma tumors in children with Neurofibromatosis type 2. The research identified 10 promising candidates, with the most favorable targets stopping tumor cell growth by impacting different cellular mechanisms.
The webinar aims to connect Asian researchers with SLAS journals, publishing opportunities, and collaboration. SLAS Discovery and SLAS Technology journals are two peer-reviewed, open-access journals publishing innovative research and technologies.
By creating virtual cells from 4D AI models and digital twins, researchers can predict how mitochondria respond to drug treatment, grouping cells that respond similarly together. This technology has the potential to speed up drug discovery and accelerate research for diseases such as cancer, diabetes, and Alzheimer's.
The conference will explore next-generation biologics and immunotherapies, targeted protein modulation, and emerging therapies for oncogenic drivers. Experts will discuss the role of artificial intelligence in accelerating therapeutic development.
Researchers developed a flexible metal–organic framework, APF-40, to analyze large pharmaceutical molecules with complex structures. The framework enables the determination of structures from microgram-scale samples, aiding drug discovery and natural products research.
A study found that CADD522 strengthened bones in post-menopausal mice while reducing body fat and reversing metabolic changes linked to menopause. The treatment also appeared to reverse menopause-related changes in fatty acids and lipid abnormalities.
Researchers at Helmholtz Munich have identified a tumor protein called ADAMTSL4 as a key driver of cancer cachexia, a wasting process that affects muscle and fat tissue. The protein locally activates the TGF-β signaling pathway, triggering a catabolic program that promotes muscle and fat breakdown.
A new high-throughput tool developed by Stanford University scientists can detect small changes in protein levels within cells, enabling faster and more efficient drug discovery. By amplifying these changes, researchers can identify potential therapeutic targets for diseases like cancer, potentially leading to breakthroughs in treatment.
Researchers have created a high-resolution functional map of human immune cells, revealing intricate circuits that govern health and disease. The dataset provides a powerful framework for designing cancer immunotherapies and treating autoimmune conditions, and serves as a foundation for AI models of biology.
Researchers at Purdue University have developed L-32, a quinolone-based inhibitor that targets PTPN22, a negative regulator of the immune system. This compound promotes robust antitumor immunity and has improved potency, selectivity, and cellular efficacy compared to previous derivatives.
The 13th Aging Research and Drug Discovery Meeting (ARDD) 2026 will bring together leading researchers, clinicians, and industry experts to advance aging research and accelerate age-related disease interventions. Aging is proud to support ARDD as a media partner, promoting the event through its digital and social media channels.
Surzen Biotherapeutics aims to develop effective pain relief without severe side effects by targeting opioid receptor pathways differently. The company plans to use peptides to block dimerization, reducing tolerance and improving efficacy.
Researchers developed a new molecular editing strategy that relocates the nitrogen atom within the pyridine ring, creating positional isomers. This approach preserves substituents while altering properties such as solubility and interactions with biological targets.
Researchers from the University of Rochester's TraCe-bMPS have developed tissue chips that can predict dangerous immune reactions to cancer therapies. The technology, which uses human cells and sensors, has been accepted into the FDA's Innovative Science and Technology Approaches for New Drugs pilot program.
The new integrations provide enterprise AI agents direct access to live, structured research data from Dimensions' 430M+ interconnected records. This allows for AI-assisted analytics across one of the world's most comprehensive linked views of global research activity.
Researchers have found a new compound that promotes joint health and reduces inflammation-related genes in a model of osteoarthritis. The drug, M04, has shown promise as an innovative OA therapy by slowing down the disease process, giving people more years of pain-free living.
Scientists at Gladstone Institutes have developed a regenerative treatment using stem cell-derived spinal interneurons to repair damaged neural networks in rats. The new cells not only survived and formed connections with the animals' own neural circuits but also improved breathing-related motor function after transplantation.
Researchers created nearly 700 new cancer models derived from patient tumors to aid in drug development. The models, representing 25 types of cancer, are now available for global use, providing a resource for identifying new drug targets and testing potential treatments.
A study at USC discovers a common genetic variant in Indigenous American populations that silences the microprotein MENTSH, restoring it improves insulin signaling and blocks diet-induced weight gain. MENTSH-based therapies could offer a precision-medicine approach to Type 2 diabetes.
Researchers found that even losing one copy of the TBX5 gene can drastically derail heart development due to DNA misfolding. The study reveals a new origin for genetic disease, suggesting that small drops in protein levels can scramble the 3D structure of DNA.
Revolver Therapeutics, a spin-out company from the University of Bath, has won the Health category of the Royal Society of Chemistry's Emerging Technologies Competition with its proprietary discovery platform. The platform generates and tests millions of constrained peptide drug candidates directly inside living cells, selecting for mo...
A review study reveals diverse metabolite families containing atypical atoms, including fluorine, selenium, arsenic, and boron, with distinct biological functions and properties. These elements shape natural products with structural and functional versatility, paving ways toward sustainable biotechnologies.
Researchers have identified a widespread source of error in a popular genome study method and created a machine-learning tool to correct it. PATTY uses machine learning to reduce artifacts while preserving real signals in noisy data, giving researchers a clearer view of gene activity control.
SLAS Discovery highlights innovative screening platforms accelerating therapeutic discovery for neurodegenerative diseases, including a newly identified link to Alzheimer's progression. The journal showcases novel technologies and approaches to understand and treat human disease, advancing life sciences discovery and technology.
This volume of SLAS Technology highlights novel laboratory technologies, open-source software, and disease-specific tools for advancing life sciences research and development. The journal emphasizes the importance of education, knowledge exchange, and global community building to drive innovation in biomedical research.
Researchers at Texas A&M University have found a way to intervene early in traumatic brain injuries using a natural, gut-derived chemical that prevents post-traumatic epilepsy from taking root. The treatment reduced brain inflammation, improved memory and mood, protected brain cells, made seizures both rarer and harder to trigger.
Deep learning models accelerate drug design, predict chemical interactions, and engineer stable candidates. AI-powered simulations optimize dosimetry, predicting biodistribution and generating patient-specific digital twins for individualized treatment planning.
Researchers developed a human-safe drug that repairs DNA breaks and reduces inflammation in a mouse model of Alzheimer's disease. The approach targets multiple disease-relevant cellular pathways, providing a broader therapeutic strategy than previous approaches focused on individual disease hallmarks.
Scientists at King's College London have developed a human-safe drug that repairs DNA breaks and reduces inflammation in a mouse model of Alzheimer's disease. This approach targets multiple features of the disease simultaneously, providing a broader therapeutic strategy than previous approaches focused on individual disease hallmarks.
Researchers discovered a potential drug developed at Michigan Medicine reverses metabolic dysfunction-associated steatohepatitis (MASH) in animal models by disrupting the disease-driving pathway that links the gut and liver. DT-109 improved gut health, reducing inflammation in livers of nonhuman primates.
A team of researchers has developed a new method for finding effective tuberculosis drugs by leveraging the PAC-MAN technique and artificial intelligence. The approach uses machine learning models to predict which chemical compounds can penetrate the outer membrane of the bacteria, paving the way for more efficient drug discovery.
BetaDescribe, an AI system, converts protein sequences into detailed textual descriptions of their functions and characteristics. The technology helps bridge the gap between characterized and existing proteins in nature, enabling researchers to rapidly generate evidence-based hypotheses regarding unknown proteins.
A USC interdisciplinary team has identified a promising pathway to turn off brain inflammation before it does its damage, increasing the risk of late-onset Alzheimer's. The Norman and Mary Pattiz Foundation funding will support research on novel drug discovery, early detection, and prevention of Alzheimer's disease.
A team from the University of Osaka has created a high-throughput platform to engineer versatile biosensors that can track lipid molecules in living cells. This method, called Cell surface Liposome Binding (CLiB) assay, uses yeast cells and fluorescence readouts to test protein variants' binding to lipids.
Researchers at Texas A&M University develop a laser technique called TRIP to directly measure quantum forces shaping proteins, enabling accurate prediction of how pharmaceutical drugs interact with them. This breakthrough could lead to the design of medicines tailored to specific diseases, revolutionizing precision medicine.
A POSTECH research team has created an automated, modular system for assembling reconstituted cell-free systems, significantly reducing costs by 95% and preparation time to 2 days. This innovation enables the customization of individual components, paving the way for improved biologically engineered high-value therapeutics.
Researchers develop cellular model to reproduce NF1-associated tumour progression, identifying new therapeutic opportunities. The combination of olaparib and selumetinib shows promise in reducing tumour growth.
Universities and hospitals conduct substantial numbers of late-stage clinical trials to repurpose generic drugs at reduced costs. This research has huge potential to provide society with affordable treatments for various conditions.
Researchers at Purdue University have developed a next-generation technology platform designed to dramatically accelerate one of the slowest stages of cancer drug discovery. The platform combines chemical synthesis, biological testing, and mass spectrometry into a single integrated workflow, allowing researchers to generate, evaluate, ...
Terasaki Institute researchers and key pioneers publish comprehensive review on glioma organoid models, proposing a foundational classification framework to guide translational brain tumor research. The review provides an overview of human glioma organoid systems and aims to address methodological heterogeneity in the field.
The University of Virginia has joined SPARK GLOBAL to leverage resources and expertise in accelerating the development of new medicines. This collaboration aims to reduce time from lab discoveries to clinic trials, delivering tangible healthcare solutions to patients.
The International Society for Stem Cell Research announces the launch of a global consortium focused on integrating human stem cell-derived models into preclinical drug development. Bayer is a founding member, aiming to establish standardized frameworks and regulatory guidance for these models.
A large-scale Phase 3 trial of CRISPR therapy has shown an 87% reduction in attacks for patients with hereditary angioedema. The treatment also improved quality-of-life scores and reduced the need for on-demand medication, paving the way for future genetic therapies.
Physicists at UC Berkeley introduce phase contrast to electron microscopy, enabling clearer images of small molecules and structures inside cells. The laser phase plate enhances cryoelectron microscopy, overcoming signal-to-noise limitations and paving the way for new drug discovery.
The Acceleration Consortium and Structural Genomics Consortium collaborate to develop new drugs using AI-driven lab capabilities. The partnership aims to speed up the discovery of bioactive molecules, advancing human health and disease understanding.
Scripps Research team creates stereoretentive radical-radical cross-coupling, a simpler way to build chiral drug candidates while maintaining 3D structure. The new reaction uses a nickel catalyst and produces practical yields with high enantiospecificity.
Researchers summarize recent developments in terahertz biophotonics, highlighting its potential for overcoming technical limitations in fields like skin cancer diagnosis, wound assessment, and drug discovery. The study provides a roadmap for future research to improve the field's practical applications.
Researchers at IRB Barcelona used AI to design new chemical entities that selectively target specific cell types, demonstrating superior activity compared to conventional screening strategies. The methodology, called phenotypic discovery, uses observable responses in cells rather than a specific molecular target.
Andrew Yang's research has reshaped scientific understanding of the blood-brain barrier and its role in brain health and disease. His latest study reveals new potential treatment targets for neurological diseases, normal aging, and sleep.
Researchers at King's College London have developed a new approach called 'Efflux Resistance Breaker' (ERB), designed to overcome one way bacteria escape antibiotic treatment. This allows antibiotics to remain inside bacterial cells at higher concentrations, restoring their ability to kill bacteria even with resistance mechanisms present.
Two projects, BOOST-HP and BIONIC, use machine learning to analyze large datasets of medication exposure and outcomes. The findings highlight the need for more data and cautious design of machine learning models to accurately assess potential links between medications and pregnant women.
Researchers are using 3D cardiac constructs to model cardiovascular diseases and test new drugs. These constructs can capture the complexity of human cardiac tissue, including its electrical activity, metabolism, and cellular communication. The field is advancing with biomaterials, AI-assisted screening, and improved standardization.
Researchers at Memorial Sloan Kettering Cancer Center have uncovered promising combination therapies for a rare childhood brain tumor by analyzing patient samples, cell models, and laboratory data. The study found that cancer cells can develop workarounds to evade targeted RAS therapies, highlighting the need for new treatment strategies.